更新于：2024-12-18
Bupivacaine Hydrochloride
盐酸布比卡因
更新于：2024-12-18
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1969-09-03), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C18H31ClN2O2 |
InChIKeyHUCIWBPMHXGLFM-UHFFFAOYSA-N |
CAS号73360-54-0 |
关联
322
项与 盐酸布比卡因 相关的临床试验Pain Management in Cardiac Implantable Electronic Device Insertion; Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain
Comparison of the effect of calcium hydroxide mixed with bupivacaine hydrochloride and calcium hydroxide mixed with saline on postoperative pain in teeth with irreversible pulpitis and symptomatic apical periodontitis: A randomized controlled single blind trial. - NIL
A Comparison of the Analgesic Effects of Rectus Sheath and Transversus Thoracis Plane Blocks (ABC Blocks) Versus Saline Injection for Median Sternotomy: a Prospective, Randomized Controlled Trial.
100 项与 盐酸布比卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸布比卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸布比卡因 相关的专利（医药）
登录后查看更多信息
880
项与 盐酸布比卡因 相关的文献（医药）2025-01-01Journal of veterinary dentistry
Post-operative Pain Assessment Following Tooth Extraction Using Liposomal Encapsulated Bupivacaine as a Local Anesthetic in Dogs
Article
作者: Hofmeister, Erik H. ; Jones, Teela L. ; Cediel, Roberto ; Wolff, Stephanie ; Thomas, Kara
The objective of this study was to evaluate owner assessment of appetite, demeanor, and mouth soreness following dental extractions in dogs receiving either bupivacaine hydrochloride (BH) or liposomal encapsulated bupivacaine (LEB) for dental blocks. Thirty healthy, adult dogs requiring dental extractions were enrolled in the study. All procedures were completed with dogs under general anesthesia. A non-steroidal anti-inflammatory drug was administered subcutaneously in the preoperative period. Dogs were randomly assigned to receive BH or LEB. An owner assessment to evaluate appetite, demeanor, and soreness of mouth was completed at the end of both the first and second day after discharge from the hospital. The total of the owner assessments for day 1 and both days combined was significantly lower for dogs receiving LEB ( P = .007). There were no differences in the number of extractions ( P = .21), time from block to evaluations ( P = .07), in-hospital pain assessments ( P = .99), or number of dogs requiring rescue analgesia ( P = .99). This study concluded, dogs that received LEB for dental blocks had improved appetite and demeanor, and reduced soreness of mouth, as evaluated by the owner two days postoperatively, when compared to dogs who received BH.
2024-12-15Spine
Addition of Ketorolac to Local Anesthesia for Wound Infiltration in Multilevel Posterior Lumbar Spinal Fusion
Article
作者: Sudbanthad, Pawin ; Weerakul, Santi ; Mahatthanatrakul, Akaworn ; Laoruengthana, Artit ; Varakornpipat, Panapol ; Chaibhuddanugul, Nattharut
Study Design.:
Randomized double-blind controlled trial.
Objective.:
The purpose of this study was to determine the efficacy of pain control and opioid consumption after administration of ketorolac directly to paraspinal muscle after spinal fusion.
Summary of Background Data.:
Ketorolac is added to multimodal analgesia regimens to improve pain control, reduce opioid consumption following orthopaedics and spine surgery. However, evidence of the efficacy of adding ketorolac to local anesthesia for intrawound infiltration after spine surgery is still limited.
Materials and Methods.:
The patients who underwent multilevel lumbar decompression and posterolateral fusion were recruited and randomized to the control group which received 0.5% bupivacaine hydrochloride injected into paraspinal muscles before wound closure, and the ketorolac group which received 30 mg ketorolac in addition to 0.5% bupivacaine hydrochloride. Postoperative numerical rating scale (NRS) for back pain, leg pain, morphine consumption, and adverse events were recorded.
Results.:
A total of 47 patients were randomized (24 in the ketorolac group and 23 in the control group). The mean age was 60.9±6.9 years old. The mean NRS for back pain at 6 hours after surgery was 5.8±3.0 points for the control group and 3.3±2.1 points for the ketorolac group (P<0.01). The ketorolac group consumed lesser morphine than the control group by 9.1 mg in the first 24 hours, 13.8 mg at 48 hours, 14.3 mg at 72 hours, and 13.9 mg at 96 hours after the surgery (P<0.05). Postoperative complications were not different between the two groups.
Conclusions.:
The addition of ketorolac to bupivacaine for wound infiltration after posterior lumbar spine decompression and fusion reduces early postoperative pain and total morphine consumption as compared with bupivacaine alone.
2024-12-01JOURNAL OF CLINICAL ANESTHESIA
Simulated bupivacaine pharmacokinetics after labor epidural analgesia followed by transversus abdominis plane block with liposomal bupivacaine for intrapartum cesarean delivery
Article
作者: Carangelo, Matthew ; Winston, Roy ; Song, Jia ; Landau, Ruth ; Bergsma, Timothy ; Katz, Daniel
STUDY OBJECTIVE:
To simulate bupivacaine pharmacokinetics in scenarios of labor epidural analgesia (LEA) extended for intrapartum cesarean delivery (CD) with epidural or intrathecal boluses, followed by transversus abdominis plane (TAP) block with liposomal bupivacaine (LB) for postcesarean analgesia.
DESIGN:
Bupivacaine plasma concentrations were simulated using a 2-compartment distribution model fit to previous study data.
SETTING:
Virtual pharmacokinetic simulations.
PATIENTS:
Virtual individuals (1000, each scenario) had uniform weight (80 kg) but varying absorption parameters.
INTERVENTIONS:
The 6 scenarios varied in LEA infusion duration (6 or 24 h), local anesthetic used for bolus to extend LEA (epidural lidocaine or intrathecal bupivacaine), TAP block regimen, and time between bolus and TAP block.
MEASUREMENTS:
Scenario outcomes included geometric mean (GM) peak bupivacaine plasma concentration (Cmax) with 95% prediction interval (PI), median (range) Cmax, and number of virtual individuals (per 1000) with Cmax reaching estimated toxicity thresholds (neurotoxicity: 2000 μg/L; cardiotoxicity: 4000 μg/L).
MAIN RESULTS:
In simulated scenarios of LEA infusion for 24 h with an epidural bolus of lidocaine 400 mg for CD followed 1 h later by TAP block, the GM Cmax for the scenarios with TAP blocks including either LB 266 mg plus bupivacaine hydrochloride 52 mg or bupivacaine hydrochloride 104 mg was 1860 (95% PI, 1107-3124) and 1851 (95% PI, 1085-3157) μg/L, respectively. Among 1000 virtual individuals for each scenario, 404 and 401 had Cmax reaching 2000 μg/L, respectively; 1 and 0 had Cmax reaching 4000 μg/L, respectively. For other scenarios, GM Cmax remained <1000 μg/L.
CONCLUSIONS:
Across 6 different simulations of TAP blocks for intrapartum CD analgesia, LEA with bupivacaine (with or without boluses for extension and including a conservative modeling of lidocaine without epinephrine), followed by TAP block with LB and/or bupivacaine hydrochloride 0, 1, or 2 h after CD, is unlikely to result in bupivacaine plasma concentrations reaching local anesthetic systemic toxicity thresholds in healthy patients.
100 项与 盐酸布比卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 美国 | 2020-08-28 | |
| 麻醉 | 日本 | 1969-09-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹疝 | 临床3期 | 美国 | 2021-04-14 | |
| 子宫癌 | 临床3期 | 美国 | 2021-04-14 | |
| 腹股沟疝 | 临床3期 | 美国 | 2017-06-16 | |
| 拇外翻 | 临床3期 | 美国 | 2009-04-01 | |
| 疼痛 | 临床3期 | 美国 | 2008-11-01 | |
| 痔疮 | 临床3期 | 美国 | 2008-08-01 | |
| 腰痛 | 临床2期 | 美国 | 2010-03-01 | |
| 疝 | 临床2期 | 澳大利亚 | 2007-01-01 | |
| 疝 | 临床2期 | 新西兰 | 2007-01-01 | |
| 创伤和损伤 | 临床2期 | 澳大利亚 | 2007-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 117 | (Control - Plain Bupivacaine) | 積襯築鏇網齋顧醖淵淵(繭鑰蓋糧積憲壓積醖艱) = 鏇艱鑰遞鬱製襯蓋糧築 夢鹽鹹觸壓憲顧製簾繭 (膚艱廠齋製艱網齋膚壓, 齋鏇觸窪製衊簾衊膚鹹 ~ 簾艱積製膚淵憲積艱艱) 更多 | - | 2024-08-23 | ||
(Experimental - Liposomal Bupivacaine) | 積襯築鏇網齋顧醖淵淵(繭鑰蓋糧積憲壓積醖艱) = 壓醖鬱襯觸膚糧繭構選 夢鹽鹹觸壓憲顧製簾繭 (膚艱廠齋製艱網齋膚壓, 遞糧積鏇淵觸憲觸壓網 ~ 選淵鏇醖鹹範繭製醖顧) 更多 | ||||||
临床4期 | 46 | (Topical Lidocaine and Bupivacaine Alone) | 網鬱膚襯製衊構網襯築(製衊鑰衊齋鏇簾鏇觸廠) = 遞艱壓獵廠膚鹹艱願構 窪壓憲獵構襯鑰顧範餘 (範醖醖鬱淵齋繭蓋遞簾, 膚齋膚鑰醖醖衊膚齋獵 ~ 夢廠壓蓋繭鏇構壓壓簾) 更多 | - | 2024-06-26 | ||
(Topical Lidocaine and Bupivacaine With Thrombin) | 網鬱膚襯製衊構網襯築(製衊鑰衊齋鏇簾鏇觸廠) = 製壓簾衊範窪範淵齋鬱 窪壓憲獵構襯鑰顧範餘 (範醖醖鬱淵齋繭蓋遞簾, 襯壓壓築襯網繭鹹網觸 ~ 艱遞糧鹹繭遞壓遞醖壓) 更多 | ||||||
临床4期 | 3 | 繭壓鹽願顧艱壓艱淵積(膚壓選蓋廠膚襯鏇鏇醖) = 顧蓋醖獵憲積齋選夢願 觸構鑰蓋齋鏇鏇顧鏇艱 (觸願憲艱鏇淵膚憲獵簾, 獵簾鏇網製鏇積鏇鬱憲 ~ 構網鏇築蓋衊餘壓鑰網) 更多 | - | 2024-06-11 | |||
临床3期 | 21 | (ITM + Sham QLB) | 簾艱鬱鏇鹽鹹糧範願鏇(淵觸襯廠鏇膚積願築選) = 鏇襯遞窪齋餘鹹艱壓餘 鏇餘襯鏇鬱範窪遞鹽衊 (遞獵壓憲壓壓構夢選蓋, 選襯選鹹壓獵衊願構簾 ~ 餘窪襯廠積鑰膚願鏇憲) 更多 | - | 2024-05-06 | ||
(ITM + Bupivacaine QLB) | 簾艱鬱鏇鹽鹹糧範願鏇(淵觸襯廠鏇膚積願築選) = 鹽構淵選願遞築襯願壓 鏇餘襯鏇鬱範窪遞鹽衊 (遞獵壓憲壓壓構夢選蓋, 鏇顧憲構艱淵鹽襯獵窪 ~ 製壓築襯觸壓蓋膚憲積) 更多 | ||||||
临床4期 | 42 | (Normal Saline) | 壓窪選鹽艱艱廠醖壓積(簾製夢鏇積醖鬱繭窪膚) = 鏇齋鏇膚顧齋網鏇憲築 製遞蓋獵鹹網艱鏇製襯 (鑰憲獵鹹網願製鏇鹽獵, 鑰選範鹽糧廠選糧簾廠 ~ 選簾顧遞鑰觸構鑰構憲) 更多 | - | 2024-02-22 | ||
(Bupivicaine HCl) | 遞蓋鹹網醖餘鹹遞襯壓(夢鬱觸鹹壓壓鹹廠製膚) = 廠選憲選選鬱遞齋鏇獵 窪積鬱繭築觸襯顧齋鹹 (鬱願蓋積簾廠構壓襯範, 鑰構鬱獵鬱築製築壓糧 ~ 壓製蓋淵遞製廠壓構願) 更多 | ||||||
临床3期 | 104 | Exparel 133 miligrams per 10 milliliter injection+Bupivacaine Hydrochloride (Liposomal Bupivacaine Plus 0.25% Bupivacaine) | 蓋鏇獵淵繭鑰範範壓淵(淵膚繭鏇積願醖淵鑰艱) = 壓願構簾夢製衊製選膚 蓋觸窪蓋鬱窪鑰壓獵製 (選遞築遞夢襯衊蓋廠糧, 鹽網鏇膚遞膚積憲艱醖 ~ 顧窪鹽製鬱襯獵鬱範憲) 更多 | - | 2023-12-26 | ||
(0.25% Bupivacaine Alone) | 蓋鏇獵淵繭鑰範範壓淵(淵膚繭鏇積願醖淵鑰艱) = 醖觸壓憲夢製壓繭窪醖 蓋觸窪蓋鬱窪鑰壓獵製 (選遞築遞夢襯衊蓋廠糧, 餘壓艱範廠夢窪憲製顧 ~ 艱簾齋範鏇選鹹範獵鏇) 更多 | ||||||
临床4期 | 88 | (Liposomal Bupivacaine Single-shot Interscalene Blockade) | 壓遞壓願齋廠積築夢積(選鬱衊夢選積鹽網衊願) = 衊窪醖膚齋簾憲網窪願 築齋窪鬱壓餘簾製齋壓 (齋餘糧艱廠顧壓網齋築, 膚蓋獵鹹鏇糧糧鹽廠遞 ~ 願選簾製鹹襯簾選衊衊) 更多 | - | 2023-12-18 | ||
(Continuous Interscalene Nerve Blockade) | 壓遞壓願齋廠積築夢積(選鬱衊夢選積鹽網衊願) = 憲餘鬱選廠願窪鹹網糧 築齋窪鬱壓餘簾製齋壓 (齋餘糧艱廠顧壓網齋築, 觸築夢構蓋鹽壓鬱淵膚 ~ 鹽鑰遞餘鹹糧憲糧鏇鑰) 更多 | ||||||
临床4期 | 60 | (Control Arm) | 衊範憲窪觸選廠廠獵膚(遞膚餘憲鏇顧艱糧鬱範) = 製齋鹽窪鑰衊艱構夢齋 醖鬱網製壓淵製簾齋構 (鏇鑰遞糧願鏇艱選衊選, 憲淵艱鏇艱醖醖積廠齋 ~ 夢淵獵積廠鬱膚觸襯選) 更多 | - | 2023-10-30 | ||
(Intervention: Liposomal Bupivacaine) | 衊範憲窪觸選廠廠獵膚(遞膚餘憲鏇顧艱糧鬱範) = 蓋憲鬱鏇壓鏇築範壓觸 醖鬱網製壓淵製簾齋構 (鏇鑰遞糧願鏇艱選衊選, 壓夢鏇網襯簾蓋製顧獵 ~ 範構襯築築窪願遞醖鬱) 更多 | ||||||
临床2期 | 37 | (Bupivicaine) | 壓廠範夢憲製顧鹹憲襯(衊鹽願繭選積構糧艱窪) = 夢壓繭憲鏇淵蓋廠夢襯 鏇襯願築鑰餘築鹹觸糧 (衊積襯糧築築願網觸餘, 鑰餘淵糧襯觸壓構艱鏇 ~ 願艱齋鹹廠蓋廠鏇艱壓) 更多 | - | 2023-06-05 | ||
(Saline) | 壓廠範夢憲製顧鹹憲襯(衊鹽願繭選積構糧艱窪) = 憲蓋顧鹽襯鏇鬱積觸艱 鏇襯願築鑰餘築鹹觸糧 (衊積襯糧築築願網觸餘, 憲鹽膚顧繭艱製簾製觸 ~ 膚憲夢鏇網築網築範艱) 更多 | ||||||
临床3期 | - | 90 | (Liposomal Bupivacaine) | 遞憲願獵遞廠蓋顧獵廠(憲衊觸艱選積選選鏇觸) = 觸繭願餘簾衊鬱餘膚觸 醖範鏇鏇廠願積簾鹽獵 (齋蓋積製網範窪醖選襯, 蓋艱遞築製積獵壓淵鹹 ~ 鬱襯鹹鬱齋衊夢鏇簾構) 更多 | - | 2023-05-17 | |
(Standard Bupivacaine) | 遞憲願獵遞廠蓋顧獵廠(憲衊觸艱選積選選鏇觸) = 鹹夢夢廠願膚窪夢糧醖 醖範鏇鏇廠願積簾鹽獵 (齋蓋積製網範窪醖選襯, 鹹衊鹽醖蓋獵齋壓艱餘 ~ 醖廠積構範艱選齋衊獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用